ASBP

Aspire Biopharma Holdings, Inc. (ASBP) Scenario Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Base Case

Strong liquidity with current ratio of 7.99 and cash ratio of 7.22 supports near-term resilience.

Balance sheet remains debt-free with debt-to-equity of 0 and net debt-to-EBITDA of -3.70.

Profitability is highly volatile, with negative EBIT margin of -64.66% and net margin of -113.14% offset by positive gross margin of 18.35%.

Bull Case

Cash per share of 11.72 and book value per share of 11.33 provide downside support relative to the share price.

Free cash flow metrics are weak but not catastrophic, with price-to-free-cash-flow at -0.14 and operating cash flow coverage still positive on a TTM basis.

A low price-to-book ratio of 0.79 suggests the market is assigning limited value to the asset base.

Bear Case

Operating performance remains weak, with operating margin of -72.60% and interest coverage of -0.76 indicating ongoing earnings stress.

Asset efficiency is extremely poor, with asset turnover of 0.007 and working capital turnover of 0.012.

Negative earnings yield of -1.18 and free cash flow yield of -6.92 highlight continued valuation and cash generation risk.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →